Value of primordial and primary prevention for cardiovascular disease: A policy statement from the American Heart Association

Circulation

Volumn 124, Issue 8, 2011, Pages 967-990

  Weintraub, William S ^a   Daniels, Stephen R ^a   Burke, Lora E ^a   Franklin, Barry A ^a   Goff, David C ^a   Hayman, Laura L ^a   Lloyd Jones, Donald ^a   Pandey, Dilip K ^a   Sanchez, Eduardo J ^a   Schram, Andrea Parsons ^a   Whitsel, Laurie P ^a  

^a NONE

Author keywords

AHA Scientific Statements; cardiovascular diseases; prevention

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; METFORMIN; THIAZIDE DIURETIC AGENT;

BEHAVIOR CHANGE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMMUNITY CARE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIETARY INTAKE; EDUCATIONAL STATUS; EXERCISE; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; LIPID ANALYSIS; MEDICAL CARE; MEDICAL SOCIETY; NICOTINE REPLACEMENT THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; SALT INTAKE; SCHOOL; SCREENING TEST; SMOKING CESSATION;

AMERICAN HEART ASSOCIATION; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; RISK FACTORS; RISK REDUCTION BEHAVIOR; UNITED STATES;

EID: 80052171475     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0b013e3182285a81     Document Type: Review

References (227)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
2. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-798.
3. Strasser T. Reflections on cardiovascular diseases. Interdiscip Science Rev. 1978;3:225-230.
4. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K; American Heart Association. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003;107:1562-1566. (Pubitemid 36378499)
5. Task Force on Research in Prevention of Cardiovascular Disease Task Force. National Heart, Lung, and Blood Institute task force report on research in prevention of cardiovascular disease. http://www.nhlbi.nih. gov/resources/docs/cvdrpt.htm. Accessed March 15, 2011.
6. The Patient Protection and Affordable Care Act, Pub L No. 111-148, 119-124 Stat 1025.
7. Prevention for a Healthier America: Investments in Disease Prevention Yield Significant Savings, Stronger Communities. Washington, DC: Trust for America's Health; 2008.
8. Baicker K, Cutler D, Song Z. Workplace wellness programs can generate savings. Health Aff (Millwood). 2010;29:304-311.
9. Brown HS 3rd, Perez A, Li YP, Hoelscher DM, Kelder SH, Rivera R. The cost-effectiveness of a school-based overweight program. Int J Behav Nutr Phys Act. 2007;4:47. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2098777/. Accessed June 24, 2011.
10. Wang LY, Yang Q, Lowry R, Wechsler H. Economic analysis of a school-based obesity prevention program. Obes Res. 2003;11: 1313-1324. (Pubitemid 41127352)
11. Wang G, Macera CA, Scudder-Soucie B, Schmid T, Pratt M, Buchner D. A cost-benefit analysis of physical activity using bike/pedestrian trails. Health Promot Pract. 2005;6:174-179.
12. Roux L, Pratt M, Tengs TO, Yore MM, Yanagawa TL, Van Den Bos J, Rutt C, Brownson RC, Powell KE, Heath G, Kohl HW 3rd, Teutsch S, Cawley J, Lee IM, West L, Buchner DM. Cost effectiveness of community-based physical activity interventions. Am J Prev Med. 2008; 35:578-588.
13. Hagberg LA, Lindholm L. Cost-effectiveness of healthcare-based interventions aimed at improving physical activity. Scand J Public Health. 2006;34:641-653. (Pubitemid 44834980)
14. Graves N, Barnett AG, Halton KA, Veerman JL, Winkler E, Owen N, Reeves MM, Marshall A, Eakin E. Cost-effectiveness of a telephonedelivered intervention for physical activity and diet. PLoS One. 2009; 4:e7135. http://www.ncbi.nlm. nih.gov/pmc/articles/PMC2744997/. Accessed June 24, 2011.
15. Dall TM, Fulgoni VL 3rd, Zhang Y, Reimers KJ, Packard PT, Astwood JD. Potential health benefits and medical cost savings from calorie, sodium, and saturated fat reductions in the American diet. Am J Health Promot. 2009;23:412-422.
16. Baker KM, Goetzel RZ, Pei X, Weiss AJ, Bowen J, Tabrizi MJ, Nelson CF, Metz RD, Pelletier KR, Thompson E. Using a return-on-investment estimation model to evaluate outcomes from an obesity management worksite health promotion program. J Occup Environ Med. 2008;50: 981-990.
17. Ahmad S, Franz GA. Raising taxes to reduce smoking prevalence in the US: a simulation of the anticipated health and economic impacts. Public Health. 2008;122:3-10. (Pubitemid 350246234)
18. Behan DF, Eriksen MP, Lin Y. Economic effects of environmental tobacco smoke. http://www.soa.org/files/pdf/ETSReportFinalDraft(Final%203).pdf. Accessed January 5, 2011.
19. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: US Department of Health and Human Services Public Health Service; May 2008.
20. American Lung Association. Smoking cessation policy: the economic benefit. http://www.lungusa.org/stop-smoking/tobacco-controladvocacy/reports- resources/cessation-economic-benefits/states/unitedstates. html. Accessed March 16, 2011.
21. Land T, Rigotti NA, Levy DE, Paskowsky M, Warner D, Kwass JA, Wetherell L, Keithly L. A longitudinal study of Medicaid coverage for tobacco dependence treatments in Massachusetts and associated decreases in hospitalizations for cardiovascular disease. PLoS Med. 2010;7:e1000375.
22. Ruger JP, Emmons KM. Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review. Value Health. 2008;11:180-190. (Pubitemid 351473613)
23. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003; 290:1884-1890. (Pubitemid 37430605)
24. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33:1872-1894.
25. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. (Pubitemid 34437694)
26. Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150:243-254.
27. Grover S, Coupal L, Lowensteyn I. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective? Can J Cardiol. 2008;24:891-898.
28. Newman J, Grobman WA, Greenland P. Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and costeffectiveness model. Prev Cardiol. 2008;11:36-41.
29. Darnton-Hill I, Nishida C, James WP. A life course approach to diet, nutrition and the prevention of chronic diseases. Public Health Nutr. 2004;7:101-121. (Pubitemid 38294513)
30. The National Children's Study. http://www.nationalchildrensstudy.gov/ Pages/default.aspx. Accessed March 18, 2011.
31. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med. 1998;338:1650-1656. (Pubitemid 28267909)
32. McGill HC Jr, McMahan CA, Zieske AW, Malcolm GT, Tracy RE, Strong JP. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation. 2001;103:1546-1550. (Pubitemid 32226263)
33. McGill HC Jr, McMahan CA. Determinants of atherosclerosis in the young: Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Cardiol. 1998;82:30T-36T.
34. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation. 2001; 104:2815-2819. (Pubitemid 33126656)
35. Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, Berenson GS. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA. 2003;290:2271-2276. (Pubitemid 37430559)
36. Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Mäki-Torkko N, Järvisalo MJ, Uhari M, Jokinen E, Rönnemaa T, Akerblom HK, Viikari JS. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA. 2003;290:2277-2283. (Pubitemid 37430560)
37. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340:14-22. (Pubitemid 29024679)
38. Urbina EM, Kimball TR, McCoy CE, Khoury PR, Daniels SR, Dolan LM. Youth with obesity and obesity-related type 2 diabetes mellitus demonstrate abnormalities in carotid structure and function. Circulation. 2009;119:2913-2919.
39. Juonala M, Magnussen CG, Venn A, Dwyer T, Burns TL, Davis PH, Chen W, Srinivasan SR, Daniels SR, Kähönen M, Laitinen T, Taittonen L, Berenson GS, Viikari JS, Raitakari OT. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. Circulation. 2010;122:2514-2520.
40. Centers for Disease Control and Prevention (CDC). Prevalence of abnormal lipid levels among youths: United States, 1999-2006. MMWR Morb Mortal Wkly Rep. 2010;59:29-33.
41. Din-Dzietham R, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation. 2007;116:1488-1496. (Pubitemid 47480640)
42. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003-2006. JAMA. 2008;299: 2401-2405. (Pubitemid 351749238)
43. Savoye M, Shaw M, Dziura J, Tamborlane WV, Rose P, Guandalini C, Goldberg-Gell R, Burgert TS, Cali AM, Weiss R, Caprio S. Effects of a weight management program on body composition and metabolic parameters in overweight children: a randomized controlled trial. JAMA. 2007;297:2697-2704. (Pubitemid 47001095)
44. HEALTHY Study Group, Foster GD, Linder B, Baranowski T, Cooper DM, Goldberg L, Harrell JS, Kaufman F, Marcus MD, Treviño RP, Hirst K. A school-based intervention for diabetes risk reduction. N Engl J Med. 2010;363:443-453.
45. US Department of Health and Human Services, Office of the Surgeon General. The Surgeon General's call to action to prevent and decrease overweight and obesity. http://www.surgeongeneral.gov/topics/obesity/calltoaction/fact- adolescents.htm. Accessed October 29, 2010.
46. Webber LS, Srinivasan SR, Wattigney WA, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to adulthood: the Bogalusa Heart Study. Am J Epidemiol. 1991;133:884-899.
47. Porrka KV, Viikari JS, Taimela S, Dahl, M. Akerblom K. Tracking and predictiveness of serum lipid and lipoprotein measurements in childhood: a 12 year follow up: the Cardiovascular Risk in Young Finns Study. Am J Epidemiol. 1994;140:1096-1110.
48. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med. 2003;157:821-827. (Pubitemid 36988016)
49. Salo P, Viikari J, Hämäläinen M, Lapinleimu H, Routi T, Rönnemaa T, Seppänen R, Jokinen E, Välimäki I, Simell O. Serum cholesterol ester fatty acids in 7-and 13-month-old children in a prospective randomized trial of a low-saturated fat, low-cholesterol diet: the STRIP baby project: Special Turku coronary Risk factor Intervention Project for children. Acta Paediatr. 1999;88:505-512. (Pubitemid 29289218)
50. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol: the Dietary Intervention Study in Children (DISC): the Writing Group for the DISC Collaborative Research Group. JAMA. 1995;273:1429-1435.
51. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, Sijbrands EJ, Kastelein JJ. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292:331-337. (Pubitemid 38944256)
52. Hollar D, Messiah SE, Lopez-Mitnik G, Hollar TL, Almon M, Agatston AS. Effect of a two-year obesity prevention intervention on percentile changes in body mass index and academic performance in low-income elementary school children. Am J Public Health. 2010;100:646-653.
53. Hollar D, Messiah SE, Lopez-Mitnik G, Hollar TL, Almon M, Agatston AS. Healthier options for public schoolchildren program improves weight and blood pressure in 6-to 13-year-olds. J Am Diet Assoc. 2010;110:261-267.
54. Williams CL, Hayman LL, Daniels SR, Robinson TN, Steinberger J, Paridon S, Bazzarre T. Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2002;106:143-160. (Pubitemid 34747456)
55. National Institutes of Health. National Heart, Lung, and Blood Institute. NHLBI Pediatric Guidelines for Cardiovascular Health and Risk Reduction. http://www.nhlbi.nih.gov/guidelines/cvd-ped/. Accessed June 24, 2011.
56. Barlow SE; Expert Committee. Expert Committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007; 120(suppl 4):S164-S192.
57. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases: American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106: 388-391. (Pubitemid 34778969)
58. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Piña IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D'Armiento J, Kris-Etherton PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CK, Jackson EA, Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier NA, Ofili E, Oparil S, Ouyang P, Pinn VW, Sherif K, Smith SC Jr, Sopko G, Chandra-Strobos N, Urbina EM, Vaccarino V, Wenger NK. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation. 2011;123: 1243-1262.
59. US Department of Health and Human Services. Healthy People 2020: the road ahead. http://www.healthypeople.gov/hp2020/. Accessed October 29, 2010.
60. US Preventive Services Task Force. The Guide to Clinical Preventive Services. Rockville, MD: Agency for Healthcare Research and Quality; 2009.
61. US Government Accountability Office. Medicaid Preventive Services: concerted efforts needed to ensure beneficiaries receive services. http://www.gao.gov/new.items/d09578.pdf. Accessed June 24, 2011.
62. The Patient Protection and Affordable Care Act: detailed summary. http://dpc.senate.gov/healthreformbill/healthbill04.pdf. Accessed November 1, 2010.
63. National Commission on Prevention Priorities. Identifying the most beneficial and cost-effective prevention services. http://www.prevent. org/Initiatives/National-Commission-on-Prevention-Priorities.aspx. Accessed November 1, 2010.
64. Affordable Care Act: laying the foundation for prevention. http://www.healthreform.gov/newsroom/acaprevention.html. Accessed November 1, 2010.
65. The Community Guide: what works to promote health. http://www. thecommunityguide.org/index.html. Accessed November 1, 2010.
66. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ; on behalf of the American Heart Association Advocacy Coordinating Committee, Stroke Council, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease, Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-944.
67. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209.
68. Fries JF. Aging, natural death, and the compression of morbidity. N Engl J Med. 1980;303:130-135. (Pubitemid 10076605)
69. Labarthe DR, Biggers A, Goff DC Jr, Houston M. Translating a plan into action: a Public Health Action Plan to Prevent Heart Disease and Stroke. Am J Prev Med. 2005;29(suppl 1):146-151. (Pubitemid 43021830)
70. Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence. Washington, DC: Institute of Medicine; 2009.
71. DeCicca P, Kenkel D, Mathios A. Cigarette taxes and the transition from youth to adult smoking: smoking initiation, cessation, and participation. J Health Econ. 2008;27:904-917.
72. Kubik MY, Wall M, Shen L, Nanney MS, Nelson TF, Laska MN, Story M. State but not district nutrition policies are associated with less junk food in vending machines and school stores in US public schools. J Am Diet Assoc. 2010;110:1043-1048.
73. Kumanyika SK, Obarzanek E, Stettler N, Bell R, Field AE, Fortmann SP, Franklin BA, Gillman MW, Lewis CE, Poston WC 2nd, Stevens J, Hong Y. Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (formerly the Expert Panel on Population and Prevention Science). Circulation. 2008;118:428-464.
74. Centers for Disease Control and Prevention. State indicator report on fruits and vegetables, 2009. http://www.fruitsandveggiesmatter.gov/health- professionals/statereport.html#Policy. Accessed April 28, 2011.
75. Centers for Disease Control and Prevention. State indicator report on physical activity, 2010. http://www.cdc.gov/physicalactivity/downloads/PA-State- Indicator-Report-2010.pdf. Accessed April 28, 2010.
76. Centers for Disease Control and Prevention. Breastfeeding report card: United States, 2010. http://www.cdc.gov/breastfeeding/data/reportcard. htm. Accessed April 28, 2011.
77. Centers for Disease Control and Prevention. Children's food environment state indicator report, 2011. http://www.cdc.gov/obesity/downloads/ ChildrensFoodEnvironment.pdf. Accessed April 28, 2011.
78. Local Government Actions to Prevent Childhood Obesity. Washington, DC: Institute of Medicine; 2009.
79. Robert Wood Johnson Foundation. Leadership for Healthy Communities Action Strategies Toolkit. http://www.leadershipforhealthycommunities. org/index.php?option-com-content&task-view&id-352&Itemid-154 Accessed June 24, 2011.
80. Recommended Community Strategies and Measurements to Prevent Obesity. Atlanta, GA: Centers for Disease Control and Prevention; 2009.
81. Been V, Voicu, I. The Effect of Community Gardens on Neighboring Property Values. New York, NY: New York University; 2007.
82. The Reinvestment Fund. Healthy food financing initiative. http://www.trfund.com/financing/realestate/NFFFI.html. Accessed December 13, 2010.
83. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, Goldman L. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010;362:590-599.
84. Carnethon M, Whitsel LP, Franklin BA, Kris-Etherton P, Milani R, Pratt CA, Wagner GR; on behalf of the American Heart Association Advocacy Coordinating Committee; Council on Epidemiology and Prevention; Council on the Kidney in Cardiovascular Disease; Council on Nutrition, Physical Activity and Metabolism. Worksite wellness programs for cardiovascular disease prevention: a policy statement from the American Heart Association. Circulation. 2009;120:1725-1741.
85. Anderson DR, Serxner SA, Gold DB. Conceptual framework, critical questions, and practical challenges in conducting research on the financial impact of worksite health promotion. Am J Health Promot. 2001;15:281-288. (Pubitemid 32441480)
86. Aldana SG. Financial impact of health promotion programs: a comprehensive review of the literature. Am J Health Promot. 2001;15:296-320. (Pubitemid 32441482)
87. Naydeck BL, Pearson JA, Ozminkowski RJ, Day BT, Goetzel RZ. The impact of the highmark employee wellness programs on 4-year healthcare costs. J Occup Environ Med. 2008;50:146-156. (Pubitemid 351321682)
88. Hemp P. Presenteeism: at work-but out of it. Harv Bus Rev. Oct 2004;82:49-58, 155.
89. More Than Health Promotion: How Employers Manage Health and Productivity Research. Integrated Benefits Institute; January 2010. http://www.ibiweb.org/do/ viewdocument/DocumentDetail?linkId-0&aId-D3B892D637E7BC6DC79FD1BE7F928DF7. Accessed June 24, 2011.
90. Mattke S, Balakrishnan A, Bergamo G, Newberry SJ. A review of methods to measure health-related productivity loss. Am J Manag Care. 2007;13:211-217. (Pubitemid 46608585)
91. Loeppke R, Taitel M, Haufle V, Parry T, Kessler RC, Jinnett K. Health and productivity as a business strategy: a multiemployer study. J Occup Environ Med. 2009;51:411-428.
92. Stewart WF, Ricci JA, Chee E, Morganstein D. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med. 2003;45: 1234-1246. (Pubitemid 37541937)
93. Goetzel RZ, Ozminkowski RJ. The health and cost benefits of work site health-promotion programs. Annu Rev Public Health. 2008;29:303-323. (Pubitemid 351600411)
94. Lawrence S, Boyle M, Craypo L, Samuels S. The food and beverage vending environment in health care facilities participating in the Healthy Eating, Active Communities program. Pediatrics. 2009;123(suppl 5):S287-S292.
95. Foster GD, Sherman S, Borradaile KE, Grundy KM, Vander Veur SS, Nachmani J, Karpyn A, Kumanyika S, Shults J. A policy-based school intervention to prevent overweight and obesity. Pediatrics. 2008;121: e794-e802.
96. Story M. School-based approaches for preventing and treating obesity. Int J Obes Relat Metab Disord. 1999;23(suppl 2):S43-S51. (Pubitemid 29182364)
97. Cooper KH, Everett D, Meredith MD, Kloster J, Rathbone M, Read K. Texas statewide assessment of youth fitness. Res Q Exerc Sport. 2010; 81(suppl):ii-iv.
98. Research. Active Education: Physical Education, Physical Activity and Academic Performance. Princeton, NJ: Robert Wood Johnson Foundation; 2009.
99. Shore SM, Sachs ML, Lidicker JR, Brett SN, Wright AR, Libonati JR. Decreased scholastic achievement in overweight middle school students. Obesity (Silver Spring). 2008;16:1535-1538. (Pubitemid 351915124)
100. Geier AB, Foster GD, Womble LG, McLaughlin J, Borradaile KE, Nachmani J, Sherman S, Kumanyika S, Shults J. The relationship between relative weight and school attendance among elementary schoolchildren. Obesity (Silver Spring). 2007;15:2157-2161. (Pubitemid 47402249)
101. Hobin EP, Leatherdale ST, Manske SR, Robertson-Wilson J. A multilevel examination of school and student characteristics associated with moderate and high levels of physical activity among elementary school students (Ontario, Canada). Can J Public Health. 2010;101:495-499.
102. Wagner B, Senauer B, Runge CF. Cost-savings of healthy food/beverage offerings, and empirical analysis of and policy recommendations to improve the nutrition quality of school meals. Rev Agric Econ. 2007; 29:672-688. (Pubitemid 47617337)
103. Mendoza JA, Watson K, Cullen KW. Change in dietary energy density after implementation of the Texas Public School Nutrition Policy. J Am Diet Assoc. 2010;110:434-440.
104. Davis EM, Cullen KW, Watson KB, Konarik M, Radcliffe J. A Fresh Fruit and Vegetable Program improves high school students' consumption of fresh produce. J Am Diet Assoc. 2009;109:1227-1231.
105. Matson-Koffman DM, Brownstein JN, Neiner JA, Greaney ML. A site-specific literature review of policy and environmental interventions that promote physical activity and nutrition for cardiovascular health: what works? Am J Health Promot. 2005;19:167-193. (Pubitemid 40105326)
106. Naylor PJ, McKay HA. Prevention in the first place: schools a setting for action on physical inactivity. Br J Sports Med. 2009;43:10-13.
107. Commission on Social Determinants of Health: Final Report. Geneva, Switzerland: World Health Organization; September 2, 2009.
108. Lewis RJ, Huebner WW, Yarborough CM 3rd. Characteristics of participants and nonparticipants in worksite health promotion. Am J Health Promot. 1996;11:99-106. (Pubitemid 26391292)
109. Frohlich KL, Potvin L. Transcending the known in public health practice: the inequality paradox: the population approach and vulnerable populations. Am J Public Health. 2008;98:216-221. (Pubitemid 351317555)
110. Colagiuri S, Vita P, Cardona-Morrell M, Singh MF, Farrell L, Milat A, Haas M, Bauman A. The Sydney Diabetes Prevention Program: a community-based translational study. BMC Public Health. 2010;10:328. http://www.ncbi.nlm.nih. gov/pmc/articles/PMC2898827/. Accessed June 24, 2011.
111. Viigen SM, van Baal PH, Hoogenveen RT, de Wit GA, Feenstra TL. Cost-effectiveness analyses of health promotion programs: a case study of smoking prevention and cessation among Dutch students. Health Educ Res. 2008;23:310-318. (Pubitemid 351431040)
112. Janz NK, Becker MH. The Health Belief Model: a decade later. Health Educ Q. 1984;11:1-47.
113. Farrelly MC, Pechacek TF, Thomas KY, Nelson D. The impact of tobacco control programs on adult smoking. Am J Public Health. 2008; 98:304-309. (Pubitemid 351317566)
114. Centers for Disease Control and Prevention (CDC). Vital signs: nonsmokers' exposure to secondhand smoke: United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2010;59:1141-1146.
115. Committee on Secondhand Smoke Exposure and Acute Coronary Events, Institute of Medicine. Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence. Washington, DC: Institute of Medicine; 2009.
116. Lightwood JM, Coxson PG, Bibbins-Domingo K, Williams LW, Goldman L. Coronary heart disease attributable to passive smoking: CHD Policy Model. Am J Prev Med. 2009;36:13-20.
117. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Washington, DC: US Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2006.
118. Centers for Disease Control and Prevention (CDC). Smokingattributable mortality, years of potential life lost, and productivity losses: United States, 2000-2004. MMWR Morb Mortal Wkly Rep. 2008;57: 1226-1228.
119. Carpenter C, Cook PJ. Cigarette taxes and youth smoking: new evidence from national, state, and local Youth Risk Behavior Surveys. J Health Econ. 2008;27:287-299.
120. Chaloupka FJ, Cummings KM, Morley CP, Horan JK. Tax, price and cigarette smoking: evidence from the tobacco documents and implications for tobacco company marketing strategies. Tob Control. 2002; 11(suppl 1):I62-I72.
121. Goldstein LB. Physical activity and the risk of stroke. Expert Rev Neurother. 2010;10:1263-1265.
122. American College of Sports Medicine Position Stand: the recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc. 1998;30:975-991.
123. Lautenschlager NT, Cox K, Kurz AF. Physical activity and mild cognitive impairment and Alzheimer's disease. Curr Neurol Neurosci Rep. 2010;10:352-358.
124. Rejeski WJ, Brawley LR, Shumaker SA. Physical activity and healthrelated quality of life. Exerc Sport Sci Rev. 1996;24:71-108. (Pubitemid 126422671)
125. Physical Activity and Health: A Report of the Surgeon General. Washington, DC: US Department of Health and Human Services; 1996.
126. Behavioral Risk Surveillance System. Atlanta, GA: Centers for Disease Control and Prevention; 2009.
127. Cobiac LJ, Vos T, Barendregt JJ. Cost-effectiveness of interventions to promote physical activity: a modelling study. PLoS Med. 2009;6: e1000110. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700960/. Accessed June 24, 2011.
128. Pleis JR, Lucas JW. Summary health statistics for U.S. adults: National Health Interview Survey, 2007. Vital Health Stat 10. 2009;May:1-159.
129. Troiano RP, Berrigan D, Dodd KW, Masse LC, Tilert T, McDowell M. Physical activity in the United States measured by accelerometer. Med Sci Sports Exerc. 2008;40:181-188.
130. Jia H, Lubetkin EI. Obesity-related quality-adjusted life years lost in the U.S. from 1993-2008. Am J Prev Med. 2010;39:220-227.
131. Eriksson MK, Hagberg L, Lindholm L, Malmgren-Olsson EB, Osterlind J, Eliasson M. Quality of life and cost-effectiveness of a 3-year trial of lifestyle intervention in primary health care. Arch Intern Med. 2010; 170:1470-1479.
132. Sevick MA, Dunn AL, Morrow MS, Marcus BH, Chen GJ, Blair SN. Cost-effectiveness of lifestyle and structured exercise interventions in sedentary adults: results of project ACTIVE. Am J Prev Med. 2000; 19:1-8. (Pubitemid 30364991)
133. Modelling the Cost-Effectiveness of Physical Activity Interventions. London, UK: National Institute for Health and Clinical Excellence; 2006. http://www.nice.org.uk/nicemedia/pdf/FourmethodsEconomicModellingReport.pdf. Accessed April 14, 2011.
134. Muller-Riemenschneider F, Reinhold T, Willich SN. Cost-effectiveness of interventions promoting physical activity. Br J Sports Med. 2009;43: 70-76.
135. Hagberg LA, Lindholm L. Measuring the time costs of exercise: a proposed measuring method and a pilot study. Cost Eff Resour Alloc. 2010;8:9. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875204/. Accessed June 24, 2011.
136. Fogli-Cawley JJ, Dwyer JT, Saltzman E, McCullough ML, Troy LM, Meigs JB, Jacques PF. The 2005 Dietary Guidelines for Americans and risk of the metabolic syndrome. Am J Clin Nutr. 2007;86:1193-1201. (Pubitemid 47538327)
137. Fogli-Cawley JJ, Dwyer JT, Saltzman E, McCullough ML, Troy LM, Meigs JB, Jacques PF. The 2005 Dietary Guidelines for Americans and insulin resistance in the Framingham Offspring Cohort. Diabetes Care. 2007;30:817-822. (Pubitemid 46556573)
138. Millen BE, Quatromoni PA, Nam B-H, Pencina MJ, Polak JF, Kimokoti RW,
139. Imamura F, Jacques PF, Herrington DM, Dallal GE, Lichtenstein AH. Adherence to 2005 Dietary Guidelines for Americans is associated with a reduced progression of coronary artery atherosclerosis in women with established coronary artery disease. Am J Clin Nutr. 2009;90:193-201.
140. Bhupathiraju SN, Lichtenstein A, Dawson-Hughes B, Tucker KL. Adherence index based on the AHA 2006 diet and lifestyle recommendations is associated with select cardiovascular disease risk factors in older Puerto Ricans. J Nutr. 2011;141:460-469.
141. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet: DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3-10. (Pubitemid 32064838)
142. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, Stevens VJ, Vollmer WM, Lin PH, Svetkey LP, Stedman SW, Young DR; Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083-2093. (Pubitemid 37430210)
143. Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simons-Morton DG, Conlin PR, Svetkey LP, Erlinger TP, Moore TJ, Karanja N; DASHSodium Trial Collaborative Research Group. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med. 2001;135:1019-1028. (Pubitemid 33151023)
144. Esposito K, Di Palo C, Maiorino MI, Petrizzo M, Bellastella G, Siniscalchi I, Giugliano D. Long-term effect of Mediterranean-style diet and calorie restriction on biomarkers of longevity and oxidative stress in overweight men. Cardiol Res Pract. 2010:2011:293916. http://www.ncbi.nlm.nih. gov/pmc/articles/PMC3010676/. Accessed June 24, 2011.
145. Hodge AM, English DR, Itsiopoulos C, O'Dea K, Giles GG. Does a Mediterranean diet reduce the mortality risk associated with diabetes: evidence from the Melbourne Collaborative Cohort Study. Nutr Metab Cardiovasc Dis. December 29, 2011. doi: 10.1016/j.numecd.2010.10.014. http://www.ncbi.nlm.nih. gov/pubmed/21194913?dopt-Citation. Accessed June 24, 2011.
146. Knoops KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti A, van Staveren WA. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004;292:1433-1439. (Pubitemid 39258335)
147. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004;292:1440-1446. (Pubitemid 39258336)
148. Appel L. The Lewis J. Conner Memorial Lecture. Paper presented at: American Heart Association Scientific Sessions 2010; November 13-17, 2010; Chicago, IL.
149. Hammond RA, Levine R. The economic impact of obesity in the United States. Diabetes Metab Syndr Obes. 2010;3:285-295.
150. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-241.
151. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004;291:2847-2850. (Pubitemid 38747805)
152. Wadden TA, Butryn ML, Wilson C. Lifestyle modification for the management of obesity. Gastroenterology. 2007;132:2226-2238. (Pubitemid 46693750)
153. Magee CA, Iverson DC, Huang XF, Caputi P. A link between chronic sleep restriction and obesity: methodological considerations. Public Health. 2008;122:1373-1381.
154. Proceedings of the Task Force Meeting: Worksite Reviews. Atlanta, GA: Centers for Disease Control and Prevention; 2007.
155. Dannenberg AL, Burton DC, Jackson RJ. Economic and environmental costs of obesity: the impact on airlines [letter]. Am J Prev Med. 2004; 27:264. (Pubitemid 39278329)
156. Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G. Lifetime health and economic consequences of obesity. Arch Intern Med. 1999; 159:2177-2183. (Pubitemid 29483157)
157. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood) 2009;28:w822-w831.
158. Cawley J, Meyerhoefer C. The Medical Care Costs of Obesity: An Instrumental Variables Approach. Cambridge, MA National Bureau of Economic Research; 2010. NBER working paper No. 16467.
159. Cawley J. The economics of childhood obesity. Health Aff (Millwood). 2010;29:364-371.
160. Tsai SP, Ahmed FS, Wendt JK, Bhojani F, Donnelly RP. The impact of obesity on illness absence and productivity in an industrial population of petrochemical workers. Ann Epidemiol. 2008;18:8-14. (Pubitemid 350184347)
161. Trogdon JG, Finkelstein EA, Hylands T, Dellea PS, Kamal-Bahl SJ. Indirect costs of obesity: a review of the current literature. Obes Rev. 2008;9:489-500.
162. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003;289:187-193. (Pubitemid 36068706)
163. Groessl EJ, Kaplan RM, Barrett-Connor E, Ganiats TG. Body mass index and quality of well-being in a community of older adults. Am J Prev Med. 2004;26:126-129. (Pubitemid 38134439)
164. Gortmaker SL, Must A, Perrin JM, Sobol AM, Dietz WH. Social and economic consequences of overweight in adolescence and young adulthood. N Engl J Med. 1993;329:1008-1012. (Pubitemid 23307910)
165. Sabia JJ. The effect of body weight on adolescent academic performance. South Econ. 2007;73:871-900.
166. Galani C, Schneider H, Rutten FF. Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland. Int J Public Health. 2007;52:372-382. (Pubitemid 351166079)
167. Brunner E, Cohen D, Toon L. Cost effectiveness of cardiovascular disease prevention strategies: a perspective on EU food based dietary guidelines. Public Health Nutr. 2001;4:711-715. (Pubitemid 32524592)
168. Lambrew JM, Podesta JD. Promoting Prevention and Preempting Costs: A New Wellness Trust for the United States. Washington, DC: Center for American Progress; 2006.
169. Fruit and Vegetable Consumption Among Adults: United States, 2005. Atlanta, GA: Centers for Disease Control and Prevention; 2007;56: 213-217.
170. Goodpaster BH, Delany JP, Otto AD, Kuller L, Vockley J, South-Paul JE, Thomas SB, Brown J, McTigue K, Hames KC, Lang W, Jakicic JM. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA. 2010;304:1795-1802.
171. Rock CL, Flatt SW, Sherwood NE, Karanja N, Pakiz B, Thomson CA. Effect of a free prepared meal and incentivized weight loss program on weight loss and weight loss maintenance in obese and overweight women: a randomized controlled trial. JAMA. 2010;304:1803-1810.
172. Ryan DH, Kushner R. The state of obesity and obesity research. JAMA. 2010;304:1835-1836.
173. Wing RR. Treatment options for obesity: do commercial weight loss programs have a role? JAMA. 2010;304:1837-1838.
174. Javitz HS, Swan GE, Zbikowski SM, Curry SJ, McAfee TA, Decker D, Patterson R, Jack LM. Return on investment of different combinations of bupropion SR dose and behavioral treatment for smoking cessation in a health care setting: an employer's perspective. Value Health. 2004;7: 535-543. (Pubitemid 39390834)
175. Land T, Warner D, Paskowsky M, Cammaerts A, Wetherell L, Kaufmann R, Zhang L, Malarcher A, Pechacek T, Keithly L. Medicaid coverage for tobacco dependence treatments in Massachusetts and associated decreases in smoking prevalence. PLoS One. 2010;5:e9770. http://www.ncbi.nlm.nih.gov/pubmed/20305787? dopt-Citation. Accessed June 24, 2011.
176. Smoking Cessation Policy: The Economic Benefit. Washington, DC: American Lung Association; September 14, 2010.
177. West R. Smoking cessation and pregnancy. Fetal Matern Med Rev. 2002;13:181-194.
178. National Center for Health Statistics: National Health Interview Survey. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Health Statistics; 2006.
179. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:596-615.
180. American Diabetes Association. Standards of medical care in diabetes:2009. Diabetes Care. 2009;32(suppl 1):S13-S61.
181. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, Gregg E, Holman RR, Kirkman MS, Stern M, Tuomilehto J, Wareham NJ. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet. 2010;375:1365-1374.
182. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hämälä inen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344:1343-1350. (Pubitemid 32378388)
183. Saaristo T, Moilanen L, Korpi-Hyovalti E, Vanhala M, Saltevo J, Niskanen L, Jokelainen J, Peltonen M, Oksa H, Tuomilehto J, Uusitupa M, Keinänen-Kiukaanniemi S. Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care. 2010;33:2146-2151.
184. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Khunti K. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334:299. http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC1796695/. Accessed June 24, 2011.
185. Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Selfmanagement education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002;25:1159-1171. (Pubitemid 41071167)
186. Bertram M, Lim S, Barendregt J, Vos T. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for prediabetes in primary care. Diabetologia. 2010;53:875-881.
187. Smith KJ, Hsu HE, Roberts MS, Kramer MK, Orchard TJ, Piatt GA, Seidel MC, Zgibor JC, Bryce CL. Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005-2007. Prev Chronic Dis. 2010;7:A109. http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2938403/. Accessed June 24, 2011.
188. Johansson P, Ostenson CG, Hilding AM, Andersson C, Rehnberg C, Tillgren P. A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden. Int J Technol Assess Health Care. 2009;25:350-358.
189. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and costeffectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143:251-264.
190. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323-332. (Pubitemid 40293405)
191. Hoerger TJ, Zhang P, Segel JE, Gregg EW, Narayan KM, Hicks KA. Improvements in risk factor control among persons with diabetes in the United States: evidence and implications for remaining life expectancy. Diabetes Res Clin Pract. 2009;86:225-232.
192. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559. (Pubitemid 351831356)
193. Control Group; Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288-2298.
194. Hoerger TJ, Zhang P, Segel JE, Kahn HS, Barker LE, Couper S. Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. Diabetes Care. 2010;33:1933-1939.
195. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239. (Pubitemid 38924592)
196. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. Statins and all-cause mortality in high-risk primary prevention: a metaanalysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170:1024-1031.
197. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011:CD004816.
198. Forrester JS. Redefining normal low-density lipoprotein cholesterol: a strategy to unseat coronary disease as the nation's leading killer. J Am Coll Cardiol. 2010;56:630-636.
199. Pletcher MJ, Hulley SB. Statin therapy in young adults: ready for prime time? J Am Coll Cardiol. 2010;56:637-640.
200. Steinberg D. Earlier intervention in the management of hypercholesterolemia: what are we waiting for? J Am Coll Cardiol. 2010;56:627-629.
201. Manuel DG, Kwong K, Tanuseputro P, Lim J, Mustard CA, Anderson GM, Ardal S, Alter DA, Laupacis A. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ. 2006;332:1419. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1479685/. Accessed June 24, 2011.
202. Lawson KD, Fenwick EA, Pell AC, Pell JP. Comparison of mass and targeted screening strategies for cardiovascular risk: simulation of the effectiveness, cost-effectiveness and coverage using a cross-sectional survey of 3921 people. Heart. 2010;96:208-212.
203. Kang HY, Ko SK, Liew D. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions. Clin Ther. 2009;31: 2919-2930.
204. Brandle M, Davidson MB, Schriger DL, Lorber B, Herman WH. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care. 2003;26:1796-1801. (Pubitemid 36929122)
205. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761-2788. (Pubitemid 46842793)
206. National Heart, Lung, and Blood Institute. JNC 7 Express Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Washington, DC: US Department of Health and Human Services, National Institutes of Health; 2003.
207. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
208. Heidenreich PA, Davis BR, Cutler JA, Furberg CD, Lairson DR, Shlipak MG, Pressel SL, Nwachuku C, Goldman L. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Gen Intern Med. 2008;23:509-516.
209. Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B; ASCOT Investigators. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1. Pharmacoeconomics. 2009;27:221-230.
210. Preston RA, Harvey P, Herfert O, Dykstra G, Jukema JW, Sun F, Gillen D. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the Respond trial. J Clin Pharmacol. 2007;47:1555-1569. (Pubitemid 350119781)
211. Liew D, Park HJ, Ko SK. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea. Clin Ther. 2009;31:2189-2203.
212. Brownson RC, Royer C, Ewing R, McBride TD. Researchers and policymakers: travelers in parallel universes. Am J Prev Med. 2006;30: 164-172. (Pubitemid 43186014)
213. Congressional Budget Office. Changes in health habits and medical practices. In: Key Issues in Analyzing Major Health Reform Proposals. Chapter 7. http://www.cbo.gov/ftpdocs/99xx/doc9924/12-18-KeyIssues.pdf. Accessed March 16, 2011.
214. Borger C, Smith S, Truffer C, Keehan S, Sisko A, Poisal J, Clemens MK. Health spending projections through 2015: changes on the horizon. Health Aff (Millwood). 2006;25:w61-w73. (Pubitemid 43529598)
215. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH, Capewell S. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388-2398. (Pubitemid 46883773)
216. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
217. Weintraub WS, Warner CD, Mauldin PD, Becker ER, Gomes D, Cook J, Kosinski A, Boccuzzi S. Economic winners and losers after introduction of an effective new therapy depend on the type of payment system. Am J Manag Care. 1997;3:743-749. (Pubitemid 127527782)
218. Weintraub WS. Cardiovascular Health Care Economics. Totowa, NJ: Humana Press; 2003.
219. Rothermich EA, Pathak DS. Productivity-cost controversies in costeffectiveness analysis: review and research agenda. Clin Ther. 1999;21: 255-267. (Pubitemid 29106705)
220. Hlatky MA, Lipscomb J, Nelson C, Califf RM, Pryor D, Wallace AG, Mark DB. Resource use and cost of initial coronary revascularization: coronary angioplasty versus coronary bypass surgery. Circulation. 1990; 82(suppl):IV-208-IV-213.
221. Alchian A. The meaning of utility measurement. Am Econ Rev. 1953; 43:26-50.
222. Feeny DH, Torrance GW, Furlong W. Health utilities index. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA: Lippincott-Raven Press; 1996:239-252.
223. Cook TA, O'Regan M, Galland RB. Quality of life following percutaneous transluminal angioplasty for claudication. Eur J Vasc Endovasc Surg. 1996;11:191-194. (Pubitemid 26120473)
224. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programs. 2nd ed. Oxford, UK: Oxford University Press; 1997.
225. Loomes G, McKenzie L. The use of QALYs in health care decision making. Soc Sci Med. 1989;28:299-308. (Pubitemid 19053139)
226. Nease RF. Introduction to cost-effectiveness analysis alongside clinical trials: statistical and methodological issues. In: Weintraub WS, ed. Cardiovascular Health Care Economics. Totowa, NJ: Humana Press; 2003:111-121.
227. Mahoney EM, Chu, H. Cost-effectiveness analysis alongside clinical trials: statistical and methodological issues. In: Weintraub WS, ed. Cardiovascular Health Care Economics. Totowa, NJ: Humana Press; 2003:123-156.